X

Trial Profile

A global, registrational study of nomlabofusp

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 23 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nomlabofusp (Primary)
Indications Friedreich's ataxia
Focus Therapeutic Use

Most Recent Events

23 Dec 2024 New trial record
16 Dec 2024 According to a Larimar Therapeutics media release, company is in discussion with FDA on data package required to support accelerated approval, including supplementary nonclinical pharmacology investigations, and FXN, supportive PD, and safety and clinical outcomes data from the OLE study.
16 Dec 2024 According to a Larimar Therapeutics media release, Biologics License Application (BLA) submission targeted for 2H 2025 to support potential accelerated approval

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com